Next Article in Journal
Alanine-Scanning Mutagenesis of α-Conotoxin GI Reveals the Residues Crucial for Activity at the Muscle Acetylcholine Receptor
Next Article in Special Issue
Fragment-Based Structural Optimization of a Natural Product Itampolin A as a p38α Inhibitor for Lung Cancer
Previous Article in Journal
MS/MS-Based Molecular Networking Approach for the Detection of Aplysiatoxin-Related Compounds in Environmental Marine Cyanobacteria
Previous Article in Special Issue
The Anti-Angiogenic Activity of a Cystatin F Homologue from the Buccal Glands of Lampetra morii
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Mar. Drugs 2018, 16(12), 506;

Nile Tilapia Derived TP4 Shows Broad Cytotoxicity toward to Non-Small-Cell Lung Cancer Cells

Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, Ilan 262, Taiwan
The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan
Author to whom correspondence should be addressed.
Received: 16 November 2018 / Revised: 11 December 2018 / Accepted: 12 December 2018 / Published: 13 December 2018
(This article belongs to the Collection Marine Compounds and Cancer)
Full-Text   |   PDF [2318 KB, uploaded 17 December 2018]   |  


Non-small cell lung cancer (NSCLC) is among the leading causes of human mortality due to a lack of effective treatments. Conventional chemotherapies affect healthy cells and cause multidrug resistance, while tumors may eventually develop resistance to less-toxic targeted therapies. Thus, the need to develop novel therapies for NSCLC is urgent. Here, we show that Nile tilapia-derived Tilapia piscidin (TP) 4 is cytotoxic to a panel of NSCLC cells with different genetic profiles. We observed that TP4 triggers NSCLC cell death through the necrosis and combining TP4 with potent Epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitors (TKI)s, Erlotinib, and Gefitinib, improved drug responses in EGFR-mutated NSCLC cells, but not in EGFR-wild-type NSCLC cells. This work provides novel insights into potential NSCLC treatments, which may utilize antimicrobial peptide TP4 as monotherapy or in combination with EGFR-TKIs. View Full-Text
Keywords: Antimicrobial peptide (AMP); Tilapia piscidin 4 (TP4); non-small cell lung cancer (NSCLC) Antimicrobial peptide (AMP); Tilapia piscidin 4 (TP4); non-small cell lung cancer (NSCLC)

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Ting, C.-H.; Chen, J.-Y. Nile Tilapia Derived TP4 Shows Broad Cytotoxicity toward to Non-Small-Cell Lung Cancer Cells. Mar. Drugs 2018, 16, 506.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top